ArticleBriefings in bioinformatics2026
GEDO: topology-based inference of gene module activity in Sjögren's disease.
Article in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Inferring gene module activity is key to understanding transcriptomic dysregulation in case-control studies. Most existing gene set analysis methods focus on differences between groups without considering the complex geometry of the data. We introduce GEDO, a graph and topology-based method that infers gene module activity through a transition score, quantifying the shift from healthy controls to diseased individuals. When applied to bulk RNA-seq data from Sjögren's disease patients and healthy controls (PRECISESADS cohort), and a breast cancer dataset from The Cancer Genome Atlas, GEDO was benchmarked against Principal Component Analysis (PCA), the mean of z-scores, Single Sample Gene Set Enrichment Analysis (ssGSEA), and Gene Set Variation Analysis (GSVA) in classification, unsupervised clustering tasks and robustness against noise and bias. On the PRECISESADS cohort, GEDO outperformed the other approaches in predicting disease status, interferon signature, enhancing subgroup separability, and robustness against noise and bias. The biological signal captured was aligned with the knowledge and clinical features of Sjögren's disease. In the breast cancer dataset, GEDO's embeddings better represent PAM50 molecular subtypes. Its supervised and topology-based design enables finer resolution of disease-related transcriptomic alterations. GEDO offers a robust, interpretable framework for quantifying gene modules' activity, with applications in single and potentially in multi-omics integration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.